New pill targets common cancer driver in advanced tumors
NCT ID NCT06835569
Summary
This early-stage trial is testing a new oral medication called ALTA3263 in adults with advanced solid tumors that have specific KRAS mutations. The study aims to find a safe dose and see how the body processes the drug, while also checking for early signs that it might help control cancers like lung, pancreatic, and colorectal cancer. It is for people whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGOrlando, Florida, 32827, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02115, United States
-
Research Site
RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site #2
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.